Exact, Imtech, Bekaert, ThromboGenics: Benelux Equity Preview
The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.
Exact Holding NV (EXACT NA): The Dutch business-software supplier will focus on organic growth instead of making acquisitions, Het Financieele Dagblad reported, citing an interview with Chief Executive Officer Martijn Janmaat. The current board isn’t convinced the company should make big acquisitions, Het Financieele Dagblad said, citing Janmaat. Exact gained 6.6 percent to 21.20 euros.
Imtech NV (IM NA): The largest Dutch technical-services company won orders worth 23 million euros ($30.4 million) in a number of educational institutions in the Netherlands. Imtech rose 2.7 percent to 27.38 euros.
Pharming Group NV (PHARM NA): The drug developer that uses the milk of genetically modified rabbits will receive a 16.1 million-euro investment from Socius Capital Group LLC. Pharming gained 1.4 percent to 21.3 euro cents.
Royal Wessanen NV (WES NA): The Dutch maker of Beckers croquettes said Chief Financial Officer Frans Eelkman Rooda will step down on or before May 31. The company’s supervisory board will search for a successor. Wessanen rose 0.8 percent to 2.75 euros.
Bekaert NV (BEKB BB): The world’s largest maker of steel cord used in tires will sell at least 100 million euros of 4.5 percent bonds due December 2018 in a public offering to investors in Belgium and Luxembourg to fund capital spending in emerging markets and repay bank loans. Bekaert rallied 4.5 percent to 79.89 euros.
Cie. du Bois Sauvage SA (COMB BB): The investment firm lowered its holding in Ter Beke NV (TERB BB), Europe’s second- biggest supplier of sliced meat products, to less than 5 percent of voting rights as of Nov. 29. Bois Sauvage gained 0.6 percent to 203.70 euros. Ter Beke increased 1.3 percent to 61.29 euros.
ThromboGenics NV (THR BB): The Belgian drug developer focusing on eye diseases plans to raise about 35 million euros selling shares in a private placement. The size of the offering may be increased to a maximum of 2.94 million shares and share trading will be suspended pending completion of the placement. ThromboGenics rose 0.3 percent to 19.61 euros.
To contact the reporter on this story: John Martens in Brussels at email@example.com
To contact the editor responsible for this story: Angela Cullen at firstname.lastname@example.org